RAS-related protein Rab10 (RAB10) belongs to the RAS superfamily of small GTPases. RAB10 is a key regulator of intracellular membrane trafficking by orchestrating the biogenesis, transport, tethering, and fusion of membrane-bound organelles and vesicles. LRRK2-mediated phosphorylation may cause deficits in endolysosomal trafficking pathways modulated by RAB10, contributing to neurodegenerative disease onset. RAB10 is associated with Alzheimer’s disease and Parkinson’s disease.

The AlphaLISA SureFire Ultra Human and Mouse Phospho-RAB10 (Thr73) assay is a sandwich immunoassay for the quantitative detection of phospho-RAB10 (Thr73) in cellular lysates, using Alpha Technology.

Formats

• The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 μL reaction volume.

• The 500-point kit contains enough reagents to run 500 wells in 384-well format, using a 20 μL reaction volume.

• The 10,000-point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 μL reaction volume.

• The 50,000-point kit contains enough reagents to run 50,000 wells in 384-well format, using a 20 μL reaction volume.

AlphaLISA SureFire Ultra kits are compatible with

• Cell and tissue lysates

• Antibody modulators

• Biotherapeutic antibodies

Alpha SureFire kits can be used for

• Cellular kinase assays

• Receptor activation studies

• Screening

Revvity, we regard "impossibility" as inspiration and "inability" as the driving force. Revvity offers health science solutions, cutting - edge technologies and professional services, with its business covering the entire end - to - end process of scientific research exploration, development, diagnosis, and treatment. Relying on years of in - depth cultivation in fields such as translational multi - omics technology, biomarker identification, imaging, disease prediction, screening, detection and diagnosis, and informatics, Revvity is using the power of technology to break through the boundaries of human potential.

In 2023, Revvity's turnover exceeded $2.7 billion. It has more than 11,000 employees worldwide and provides diverse services for customers such as pharmaceutical and biotechnology enterprises, diagnostic laboratories, scientific research institutions and government agencies. The company is a member of the S&P 500 Index, and its customers are spread across more than 190 countries and regions around the world.